Long-term safety study of IMVT-1402 for Graves' disease
Treatments studied
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This study is a long-term extension for people with Graves' disease who already completed a previous study with the drug IMVT-1402. It aims to see how safe and effective the drug is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier study (IMVT-1402-2502 or IMVT-1402-2503).
- You cannot have stopped taking the study drug for good during that earlier study.
- You must not have met any stopping rules that would have ended your participation in the earlier study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMVT-1402 for adults with Graves' disease whose thyroid is still overactive despite taking antithyroid medication. The goal is to see if the drug can safely help control thyroid hormone levels.
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
This trial is testing a new drug, BHV-1300, to see if it works and is safe for people with Graves' disease. It might be an option if you have active hyperthyroidism (overactive thyroid) caused by Graves' disease and haven't had certain other treatments.
This trial tests a new treatment called BHV-1300 for people with Graves' disease. It aims to see if the drug is safe and works well. If you have Graves' disease confirmed by blood tests, you may be able to join.
This study looks at how well medication works for people with Graves' disease in China. It may help doctors understand the best treatment options for both new cases and relapses.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.